Literature DB >> 18406497

Indanesulfonamides as carbonic anhydrase inhibitors and anticonvulsant agents: structure-activity relationship and pharmacological evaluation.

Anne Thiry1, Stéphanie Rolin, Daniela Vullo, Aurélie Frankart, Andrea Scozzafava, Jean-Michel Dogné, Johan Wouters, Claudiu T Supuran, Bernard Masereel.   

Abstract

A small library of indanesulfonamides was screened for the inhibition of the human carbonic anhydrase (CA, EC 4.2.1.1) isoforms involved in neuronal excitation, that is, isoforms VII, XII and XIV. These CA isoforms are becoming interesting target for the design of agents useful for the treatment of epilepsy. The inhibition pattern of these indanesulfonamide compounds towards these three isoforms was excellent, with many nanomolar inhibitors detected (K(I)s in the range of 0.78-10 nM against hCA VII; 0.32-56 nM against hCA XII, and 0.47-1030 nM against hCA XIV, respectively). The maximal electroshock seizure (MES) test performed on mice showed a good anticonvulsant activity for some compounds which protected the mice against convulsions in the 50-62.5% range at a dose of 50 mg/kg. In parallel, the blood-brain barrier passive permeation of these sulfonamides was also estimated by using a computational approach.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406497     DOI: 10.1016/j.ejmech.2008.02.018

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

Review 1.  Emerging roles of Na⁺/H⁺ exchangers in epilepsy and developmental brain disorders.

Authors:  Hanshu Zhao; Karen E Carney; Lindsay Falgoust; Jullie W Pan; Dandan Sun; Zhongling Zhang
Journal:  Prog Neurobiol       Date:  2016-03-08       Impact factor: 11.685

2.  Bicarbonate contributes to GABAA receptor-mediated neuronal excitation in surgically resected human hypothalamic hamartomas.

Authors:  Do-Young Kim; Kristina A Fenoglio; John F Kerrigan; Jong M Rho
Journal:  Epilepsy Res       Date:  2008-11-20       Impact factor: 3.045

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.